Freeport-McMoRan (FCX)

Total Costs & Expenses

$18.96B

TTM · Period ending: · USD

FCX logo

FCX Total Costs & Expenses

Latest reported$18.96B
FCX TTM Total Costs & Expenses (-$112.80M → $18.96B)
High-resolution chart · PNG

FCX total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Freeport-McMoRan Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
18,961,000,000
19,085,000,000
19,451,000,000
19,152,000,000
18,969,000,000
18,377,000,000
18,592,000,000
18,249,000,000
17,747,000,000
17,517,000,000
16,625,000,000
16,679,000,000
16,394,000,000
15,770,000,000
15,739,000,000
15,378,000,000
15,014,000,000
14,972,000,000
14,514,000,000
13,904,000,000
13,151,000,000
12,022,000,000
11,976,000,000
12,249,000,000
12,499,000,000
13,467,000,000
13,721,000,000
13,600,000,000
14,093,000,000
14,147,000,000
14,064,000,000
14,256,000,000
13,774,000,000
13,250,000,000
12,590,000,000
12,482,000,000
12,584,000,000
13,618,000,000
17,970,000,000
22,366,000,000
26,700,000,000
29,257,000,000
29,298,000,000
28,891,000,000
25,875,000,000
23,622,000,000
20,341,000,000
17,088,000,000
16,936,000,000
16,216,000,000
15,570,000,000
14,549,000,000
13,097,000,000
12,531,000,000
12,164,000,000
11,779,000,000
11,780,000,000
11,694,000,000
11,606,000,000
11,283,000,000
10,929,000,000
10,372,000,000
9,914,000,000
9,725,000,000
9,132,000,000
8,870,000,000
8,460,000,000
9,543,000,000
10,966,000,000
12,176,000,000
13,541,000,000
13,171,000,000
12,841,000,000
12,814,000,000
10,580,000,000
8,329,968,000
6,047,697,000
3,373,305,000
2,891,677,000
2,671,890,000
2,324,880,000
2,110,738,000
2,001,832,000
1,913,591,000
1,841,781,000
1,808,947,000
1,682,290,000
1,549,973,000
1,417,788,000
1,346,385,000
1,360,846,000
1,368,159,000
1,381,098,000
1,298,458,000
1,270,325,000
1,242,601,000
1,241,182,000
1,319,218,000
1,293,120,000
1,298,443,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.